ALT

Altimmune, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-06

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.97USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-03-06

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-06
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
The filing itself
-214861.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
The filing itself
-164746.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.26 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.01x

1.42x

1.61x

5.23x

0.15x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-06

Sales0.01x
Its own average over 10 years, 4.3M.
Profit1.42x
Its own average over 10 years, -62.0M.
Free cash flow1.61x
Its own average over 9 years, -42.0M.
Debt5.23x
Its own average over 8 years, 6.8M.
Price0.15x
Its own average over 10 years, 13. Market data, 2026-11-05

Debt is furthest from its own average, at 5.23 times.

Sales is 0.01 times its own 10-year average; Profit is 1.42 times its own 10-year average; Free cash flow is 1.61 times its own 9-year average; Debt is 5.23 times its own 8-year average; Price is 0.15 times its own 10-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-06

Sales against its own 10-year average0.01
Source
filed
Statement
income
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
The filing itself
Profit against its own 10-year average1.42
Source
filed
Statement
income
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
The filing itself
Free cash flow against its own 9-year average1.61
Source
filed
Statement
income
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
The filing itself
Debt against its own 8-year average5.23
Source
filed
Statement
income
Fiscal year
2025
Accession
0001326190-26-000018
Reported in
USD
The filing itself
Price against its own 10-year average0.15Market data, 2026-11-05
Source
market
Taken on
2026-11-05
Reported in
USD